SWK HOLDINGS CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.23 USD | -0.69% |
|
-0.12% | -1.71% |
| 22/03 | Tranche Update on SWK Holdings Corporation's Equity Buyback Plan announced on May 16, 2023. | CI |
| 21/03 | Transcript : SWK Holdings Corporation, Q4 2023 Earnings Call, Mar 21, 2024 |
| Sales 2024 * | 38.9M 3.25B | Sales 2025 * | 41.3M 3.45B | Capitalization | 215M 17.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 23M 1.92B | Net income 2025 * | 14M 1.17B | EV / Sales 2024 * | 5.54 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 5.21 x |
| P/E ratio 2024 * |
9.31
x | P/E ratio 2025 * |
14.9
x | Employees | 23 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on SWK Holdings Corporation
More press releases
| 1 day | -0.69% | ||
| 1 week | -0.12% | ||
| Current month | -1.09% | ||
| 1 month | -1.09% | ||
| 3 months | -1.54% | ||
| 6 months | +7.69% | ||
| Current year | -1.71% |
1 week
16.80
17.35
1 month
16.7017.74
Current year
15.9218.49
1 year
15.2618.75
3 years
15.2620.49
5 years
0.0020.49
10 years
0.0045.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joe Staggs
CEO | Chief Executive Officer | 43 | 01/15/01 |
Courtney Baker
AUD | Comptroller/Controller/Auditor | - | 01/23/01 |
John David Tamas
PRN | Corporate Officer/Principal | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Laurie Dotter
CHM | Chairman | 63 | 09/22/09 |
Robert Hatcher
BRD | Director/Board Member | 61 | 15/22/15 |
| Director/Board Member | 36 | 17/21/17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 9 M€ | +6.62% | - | |
| 0.00% | 18 M€ | +3.15% | - | |
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 17.23 | -0.69% | 3,247 |
| 26/24/26 | 17.35 | +1.46% | 3,916 |
| 25/24/25 | 17.1 | +0.53% | 5,288 |
| 24/24/24 | 17.01 | -1.51% | 3,294 |
| 23/24/23 | 17.27 | +0.12% | 7,090 |
Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST
More quotes
SWK Holdings Corporation is engaged in specialty finance and asset management business. The Companyâs segments include Finance Receivables and Pharmaceutical Development. Finance Receivables segment is a healthcare capital provider, which offers customized financing solutions to a range of life science companies, institutions, and inventors. This segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Its Pharmaceutical Development segment operates through its subsidiary Enteris BioPharma, Inc. (Enteris). Enteris is a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its oral drug delivery technologies, the Peptelligence platform.
Sector
Corporate Financial Services
Calendar
15/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.23
USD
Average target price
24
USD
Spread / Average Target
+39.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.71% | 217M | |
| +8.60% | 16.07B | |
| +12.15% | 14.43B | |
| +8.15% | 9.22B | |
| -9.84% | 8.32B | |
| +0.97% | 6.07B | |
| +76.46% | 5.5B | |
| +2.27% | 4.89B | |
| +68.24% | 4.45B | |
| -6.25% | 4.08B |
- Stock Market
- Equities
- SWKH Stock
